<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT02471131</url>
  </required_header>
  <id_info>
    <org_study_id>NL.53510.068.15</org_study_id>
    <nct_id>NCT02471131</nct_id>
  </id_info>
  <brief_title>WATCHMAN Implantation During Hybrid Ablation</brief_title>
  <acronym>WINNING</acronym>
  <official_title>WATCHMAN LAAC Device Implantation During Hybrid Atrial Fibrillation Ablation</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Maastricht University Medical Center</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>Boston Scientific Corporation</agency>
      <agency_class>Industry</agency_class>
    </collaborator>
  </sponsors>
  <source>Maastricht University Medical Center</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      Atrial fibrillation (AF) is the most common cardiac arrhythmia with a lifetime risk of&#xD;
      developing AF of 1 in 4 people aged over 40. Stroke remains the most feared complication of&#xD;
      AF with an increase in risk by 5-fold, and is the leading cause of morbidity and mortality.&#xD;
      The left atrial appendage (LAA) is the origin for more than 90% of the emboli in non-valvular&#xD;
      AF. The WATCHMANâ„¢ Left Atrial Closure Device (WATCHMAN Device, Boston Scientific) reduces the&#xD;
      risk of stroke by closing off the LAA. During hybrid procedures for AF, LAA occlusion with&#xD;
      epicardial devices is known to be difficult and not free of risks.It thus will be interesting&#xD;
      to study the safety and feasibility of endocardial WATCHMAN Device implantation in a hybrid&#xD;
      ablation approach.&#xD;
    </textblock>
  </brief_summary>
  <overall_status>Completed</overall_status>
  <start_date>October 2015</start_date>
  <completion_date type="Actual">December 2016</completion_date>
  <primary_completion_date type="Actual">December 2016</primary_completion_date>
  <phase>N/A</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>N/A</allocation>
    <intervention_model>Single Group Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Major complications during follow-up, assessed by scoring the number of complications</measure>
    <time_frame>6 months</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>Device success, assessed by transesophageal echocardiogram.</measure>
    <time_frame>6 months</time_frame>
  </primary_outcome>
  <number_of_arms>1</number_of_arms>
  <enrollment type="Actual">10</enrollment>
  <condition>Atrial Fibrillation</condition>
  <condition>Stroke</condition>
  <arm_group>
    <arm_group_label>WATCHMAN Implantation</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
  </arm_group>
  <intervention>
    <intervention_type>Device</intervention_type>
    <intervention_name>WATCHMAN Device implantation</intervention_name>
    <description>The implantation of the device will be done into the left atrial appendage according to the guidelines.</description>
    <arm_group_label>WATCHMAN Implantation</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  Documented paroxysmal or (long-standing) persistent non-valvular atrial fibrillation,&#xD;
&#xD;
          -  Eligible at least for short-term OAC therapy,&#xD;
&#xD;
          -  No other conditions that would require long-term OAC therapy, suggested by current&#xD;
             standard medical practice, and thus is eligible to stop OAC if the LAA is sealed,&#xD;
&#xD;
          -  Calculated CHA2DS2-VASc score of 1 or more,&#xD;
&#xD;
          -  18 years of age or older, able and willing to provide written informed consent.&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  Current New York Heart Association Class IV Congestive Heart Failure,&#xD;
&#xD;
          -  Current thrombocytopenia (&lt; 100x10E9/L) or anemia (hemoglobin &lt;6.2 mmol/L),&#xD;
&#xD;
          -  Active infection or sepsis,&#xD;
&#xD;
          -  Resting heart rate &gt; 110 beats per minute,&#xD;
&#xD;
          -  Cerebrovascular accident (CVA) or transient ischemic attack (TIA) within the last 30&#xD;
             days,&#xD;
&#xD;
          -  Recent myocardial infarction (within 3 months),&#xD;
&#xD;
          -  Transient case of AF (i.e., secondary to recent cardiac surgery (within 3 months)),&#xD;
&#xD;
          -  Planned cardioversion 30 days post implant of the WATCHMAN Device,&#xD;
&#xD;
          -  Implanted mechanical valve prosthesis,&#xD;
&#xD;
          -  History of obliterated LAA,&#xD;
&#xD;
          -  History of heart transplantation,&#xD;
&#xD;
          -  Symptomatic carotid disease (i.e., carotid stenosis &gt;50% associated with ipsilateral&#xD;
             transient or visual ischemic attack evidenced by amaurosis fugax, ipsilateral&#xD;
             hemispheric TIAs or ipsilateral stroke within 6 months),&#xD;
&#xD;
          -  Necessity to use long-term OAC,&#xD;
&#xD;
          -  Contraindication for use of OAC or dual anti-platelet therapy,&#xD;
&#xD;
          -  Contraindication for use of aspirin,&#xD;
&#xD;
          -  Pregnancy or planned pregnancy during the course of the investigation,&#xD;
&#xD;
          -  Life expectancy less than 2 years,&#xD;
&#xD;
          -  Participation in any other clinical study involving an investigational drug or device.&#xD;
&#xD;
        Echocardiographic Exclusion Criteria (as assessed via transthoracic echocardiography (TTE)&#xD;
        or TEE) for this study are:&#xD;
&#xD;
          -  Left ventricular ejection fraction (LVEF) &lt; 30%,&#xD;
&#xD;
          -  Intracardiac thrombus as visualized by TEE within 2 days prior to implant,&#xD;
&#xD;
          -  High risk patent foramen ovale,&#xD;
&#xD;
          -  Current atrial septal defect and/or previous atrial septal repair or closure device,&#xD;
&#xD;
          -  Significant mitral valve stenosis (i.e., MV 4. 5 cm2),&#xD;
&#xD;
          -  Existing pericardial effusion of &gt;3 mm,&#xD;
&#xD;
          -  Complex atheroma with mobile plaque of the descending aorta and/or aortic arch,&#xD;
&#xD;
          -  Cardiac tumor.&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Laurent Pison, MD, PhD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Maastricht University Medical Center</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Maastricht University Medical Center</name>
      <address>
        <city>Maastricht</city>
        <state>Limburg</state>
        <zip>6229HX</zip>
        <country>Netherlands</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Netherlands</country>
  </location_countries>
  <verification_date>January 2017</verification_date>
  <study_first_submitted>May 20, 2015</study_first_submitted>
  <study_first_submitted_qc>June 10, 2015</study_first_submitted_qc>
  <study_first_posted type="Estimate">June 15, 2015</study_first_posted>
  <last_update_submitted>January 10, 2017</last_update_submitted>
  <last_update_submitted_qc>January 10, 2017</last_update_submitted_qc>
  <last_update_posted type="Estimate">January 11, 2017</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>WATCHMAN</keyword>
  <keyword>Atrial Fibrillation</keyword>
  <keyword>Hybrid Ablation</keyword>
  <keyword>Safety</keyword>
  <keyword>Feasibility</keyword>
  <keyword>Stroke Prevention</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Atrial Fibrillation</mesh_term>
  </condition_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

